<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67103">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01870739</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696A2224</org_study_id>
    <secondary_id>2012-005720-15</secondary_id>
    <nct_id>NCT01870739</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first evaluation of the effects of LCZ696 on local and regional measures of
      aortic stiffness in subjects with mild to moderate hypertension and widened pulse pressure.
      The results of this exploratory study will help to understand the mechanism of action of
      LCZ696 and used to inform the design of future clinical studies with LCZ696 in subjects with
      cardiovascular diseases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in ascending aorta distensibility at 12 weeks</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cardiovascular magnetic resonance imaging (MRI) scans will be obtained at baseline prior to randomization, at week 12 for the assessment of local aortic distensibility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in proximal descending aorta distensibility at 12 weeks</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cardiovascular magnetic resonance imaging (MRI) scans will be obtained at baseline prior to randomization, at week 12 for the assessment of local aortic distensibility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in distal descending aorta distensibility at 12 weeks</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cardiovascular magnetic resonance imaging (MRI) scans will be obtained at baseline prior to randomization, at week 12 for the assessment of local aortic distensibility.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in local aortic strain at 12 weeks</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cardiovascular magnetic resonance imaging (MRI) scans will be obtained at baseline prior to randomization, at week 12 for the assessment of local aortic strain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in regional aortic pulse wave velocity at 12 weeks</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cardiovascular magnetic resonance imaging (MRI) scans will be obtained at baseline prior to randomization, at week 12 for the assessment of regional aortic pulse wave velocity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Central blood pressure at 12 weeks</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in augmentation pressure at 12 weeks</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Augmentation pressure is the added pressure during systole due to wave reflection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in augmentation index at 12 weeks</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Augmentation index is  the percentage of the central pulse pressure due to wave reflection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulse wave velocity at 12 weeks</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with reported adverse events, serious adverse events and  death</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>LCZ696</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receiveLCZ696 once daily (q.d.) + placebo to olmesartan q.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olmesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive olmesartan once daily (q.d.) + mg placebo to LCZ696 q.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <arm_group_label>LCZ696</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan</intervention_name>
    <arm_group_label>olmesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo to LCZ696</intervention_name>
    <description>placebo</description>
    <arm_group_label>olmesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo to olmesartan</intervention_name>
    <description>placebo</description>
    <arm_group_label>LCZ696</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subjects with essential hypertension, untreated or currently taking antihypertensive
             therapy

        Key exclusion Criteria:

          -  women of child bearing potential (WOCBP) if not on highly effective contraception

          -  Malignant or severe hypertension (grade 3 of WHO classification)

          -  History or evidence of a secondary form of hypertension

          -  Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or
             any history of stroke.

          -  Previous or current diagnosis of heart failure (New York Heart Association Class
             II-IV).

        Other protocol defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luebeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 8TA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>June 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LCZ696,</keyword>
  <keyword>Hypertension,</keyword>
  <keyword>Aortic stiffness,</keyword>
  <keyword>Central blood pressure,</keyword>
  <keyword>Cardiovascular MRI</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
